louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04801914: Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive Hyperbilirubinemia Before and After PTBD
Official title: Influence of Percutaneous Biliary Drainage on the Change of Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive Hyperbilirubinemia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Matrix Metalloproteinase
Keywords: biliary drainage, matrix metalloproteinases
Lead sponsor: Institut za Rehabilitaciju Sokobanjska Beograd
Sponsor class: OTHER
Collaborators: name: Klinički centar Srbije
First posted: 2021-03-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with malignant obstructive hyperbilirubinemia admitted to hospital and referred to the interventional radiologist for percutaneous biliary drainage.

Brief summary: The purpose of this study is to detect differences in the enzymatic activity of matrix metalloproteinases in patients with malignant obstructive hyperbilirubinemia before and after percutaneous biliary drainage.

Detailed description: This study will be designed as a prospective cohort study involving the collection of peripheral blood samples before and one month after percutaneous biliary drainage for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity). Biochemical analyzes are preceded by the entry of data relevant to the research (demographic, anamnestic, clinical and biochemical).

Eligibility criteria: Inclusion Criteria:

pathological confirmation or imaging data confirming malignant disease causing bile duct obstruction, performance status 0-1

Exclusion Criteria:

terminally ill patients, performance status \>2, hepatic decompensation, severe underlying cardiac or renal diseases and coagulation disorders.

Primary outcomes:
measure: MMP-2 and MMP-9 serum activity
timeFrame: during intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Belgrade
country: Serbia
facility: University Clinical Center of Serbia
Study officials:
affiliation: Institute for chemistry in medicine, Medical school, University of Belgrade
name: Kristina Gopcevic, Phd
role: STUDY_DIRECTOR
References:
Clinical trial NCT02672514: Does MiECC Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?
Official title: Does Minimal Extracorporeal Circulation Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Kidney Injury
Lead sponsor: Herzzentrum Coswig
Sponsor class: OTHER
First posted: 2016-02-03
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to prospectively evaluate MECC compared with conventional extracorporeal circulation of diabetic patients undergoing elective coronary revascularization procedures. The investigators focused on the effects of extracorporeal circulation especially the renal function between both groups.

Detailed description: Cardiopulmonary bypass (CPB) is known having a negative influence referring to systemic inflammatory reaction after cardiac surgery which can cause acute kidney injury (AKI). Miniaturized extracorporeal circulation (MECC) attempts to reduce the adverse effects of conventional extracorporeal circulation bypass. Finally, AKI after CPB is a significant clinical problem that increasingly complicates the course of hospitalization and clinical outcome.

Eligibility criteria: Inclusion Criteria:

* diabetes mellitus type 2
* isolated elective coronary revascularization

Exclusion Criteria:

* urgent or emergent Status
* Re-Operation
* preexisting reanimation
* preexisting renal transplantation
* chronic kidney insufficiency (GFR \< 30 ml/min)
* renal cell carcinoma
* renal artery Stenosis
* heart valve disease (middle- and high-grade)
* endocarditis
* infections (HIV, Tbc and all types of Hepatitis)
* hepatic cirrhosis

Primary outcomes:
measure: Acute Kidney Injury
timeFrame: within the first 30 days (plus or minus 3 days) after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05843214: Transcranial Doppler, Optic Nerve Envelope Diameter and Quantitative Pupillometry Measurements
Official title: Transcranial Doppler, Optic Nerve Envelope Diameter and Quantitative Pupillometry Measurements in Postoperative Resuscitation Neurosurgery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neurological Complication
Lead sponsor: Centre Hospitalier Universitaire de la Réunion
Sponsor class: OTHER
First posted: 2023-05-06
Enrollment: 230
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing planned neurosurgery

Brief summary: Non-invasive neuromonitoring tools such as transcranial doppler, optic nerve envelope diameter measurement and quantitative pupillometry are routinely used in acute brain injured patients as part of multimodal neuromonitoring with the aim, among others, of detecting episodes of intracranial hypertension, each method allowing the study of one of the different pathophysiological mechanisms of its impact.

However, at present there is no data in the literature on the value of these non-invasive neuromonitoring tools in the management of patients undergoing controlled intracranial surgery.

The study aims to help the early detection of postoperative neurological deterioration.


Eligibility criteria: Inclusion Criteria:

* Regulated intracranial surgery: scheduled \> 48 hours
* French-speaking patient
* No opposition from the patient or a relative when the patient is unable to consent

Exclusion Criteria:

* Chronic subdural haematoma
* Isolated cerebral endovascular procedure
* Stereotactic biopsy
* Scheduled ventriculoperitoneal shunt or isolated ventriculocisternostomy
* Specific non-inclusion criteria for quantitative pupillometry: known pupillary abnormalities, glaucoma, cataract surgery and any ocular surgery.

Primary outcomes:
measure: Evolution of non-invasive neuromonitoring measures (using transcranial doppler)
timeFrame: From 1 hour before the surgery until Day 4 post-surgery
measure: Evolution of non-invasive neuromonitoring measures (optic nerve envelope diameter)
timeFrame: From 1 hour before the surgery until Day 4 post-surgery
measure: Evolution of non-invasive neuromonitoring measures (quantitative pupillometry)
timeFrame: From 1 hour before the surgery until Day 4 post-surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Saint-Pierre
country: Réunion
facility: CHU de la Réunion
Study officials:
affiliation: CHU de la Réunion
name: Romain ASMOLOV, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03144414: Laparoscopic Assisted Doderlin Vaginal Hysterectomy
Official title: Laparoscopic Assisted Doderlin Vaginal Hysterectomy vs. Laparoscopic Assisted Vaginal Hysterectomy: A Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Laparoscopic Hysterectomy
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2017-05-08
Enrollment: 60
Sex: FEMALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This prospective randomized clinical trial will be conducted in Ain Shams University Maternity Hospital during the period from May 2017 to December 2017. Group Ι: 30 patients will undergo conventional laparoscopic assisted vaginal hysterectomy (LAVH). Group ΙΙ: 30 patients will undergo laparoscopic assisted Doderlein vaginal hysterectomy (LADH)


Eligibility criteria: Inclusion Criteria:

* Age \> 40 years.
* Uterine size ≤ 14weeks.
* Benign uterine pathology (Fibroid uterus, endometrial hyperplasia, DUB, uterine prolapse).
* No contraindication for laparoscopic surgery.

Exclusion Criteria:

* Gynecologic malignancy.
* Contraindications to laparoscopy like any medical condition worsened by pneumoperitoneum or the Trendelenburg position.
* Large abdominal hernia
* Large ovarian mass
* History of previous laparotomy finding extensive adhesions

Primary outcomes:
measure: Operative time
timeFrame: 24 hours
Secondary outcomes:
measure: postoperative pain
timeFrame: 24 hours
measure: operative complications
timeFrame: 24 hours
measure: Hospital stay
timeFrame: 24 hours
measure: Blood loss
timeFrame: 24 hours
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
References:
Clinical trial NCT03817814: Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment
Official title: Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Fertility Preservation
Breast Cancer
Keywords: Quality of Life
Web-based questionnaire
18-461
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2019-01-28
Enrollment: 209
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is a cross-sectional survey of YWBC who received a pre-treatment consultation with a FNS from 2009 through 2018. Participants will complete a one-time web-based questionnaire examining the decisions they made about FP before and after treatment, the factors that influenced FP decisions, and the ways in which patients pursue FB after treatment.

Brief summary: This study will help the researchers learn more about factors that affect the decisions about fertility preservation and family building made by young women with breast cancer.


Eligibility criteria: Inclusion Criteria:

* Breast cancer, Stage 0-III
* Female
* 18-45 years of age at time of diagnosis
* Patients that completed their primary breast cancer treatment (surgery, chemotherapy, radiation therapy). Patients can still be on endocrine therapy, trastuzumab and/or pertuzumab therapy.
* Received education and counseling by MSK Fertility Nurse Specialist before beginning cancer treatment from 2009 through 2018

Exclusion Criteria:

* Unable to read English

Primary outcomes:
measure: Patient-reported outcome questionnaire - Fertility Preservation Questionnaire
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Shari Goldfarb, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06818214: Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MRI, FAPI PET-CT, Pathology, and AI Evaluation System
Official title: Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MRI, FAPI PET-CT, Pathology, and AI Evaluation System
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Esophageal Cancer
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2025-02-10
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients are from the Esophageal Cancer Diagnosis and Treatment Center of the Affiliated Tumor Hospital of Zhengzhou University. Data will be collected from Feburary 2025 to January 2030, from patients with biopsy-confirmed esophageal cancer. Based on clinical needs, initial staging will be performed through EUS, spectral CT, or PET-CT. Patients who are planned for direct surgery will undergo MRI within 7 days prior to surgery; patients who are planned for neoadjuvant therapy will undergo spectral CT and MRI examinations both before neoadjuvant therapy and within 7 days before surgery.

Brief summary: The objective of this study is to address the urgent issues in the diagnosis of lymph node metastasis in esophageal cancer. By employing multimodal MRI, spectral CT imaging and FAPI PET-CTtechniques, the study will correlate lymph node images with postoperative pathology results. Additionally, AI technology will be applied to learn from multimodal imaging data, enabling comprehensive analysis and evaluation of lymph node metastasis. Using a large volume of clinical and imaging data, a predictive model will be established to provide individualized lymph node metastasis risk assessments for each esophageal cancer patient. This will, in turn, offer robust support for personalized treatment strategies in esophageal cancer.


Eligibility criteria: Inclusion Criteria:

1. Consecutive patients with pathological diagnosis of esophageal cancer.
2. Patients underwent radical esophagectomy and lymph node dissection, with preoperative multimodal MRI, spectral CT and FAPI PET-CT ; patients underwent neoadjuvant therapy followed by radical surgery, with preoperative multimodal MRI, spectral CT and FAPI PET-CTboth before and after neoadjuvant therapy.
3. No history of malignant tumors or cancer-related treatments.
4. Complete postoperative pathological data, allowing for a one-to-one comparison of preoperative lymph node imaging and postoperative histopathology for evaluation.

Exclusion Criteria:

1. Contraindications for MRI, spectral CT or FAPI PET-CT.
2. Patients who refuse to participate in this study.

Primary outcomes:
measure: MRI, spectral CT and FAPI PET-CT combined with AI in prediction of lymph node status in esophageal cancer
timeFrame: February 2025 - January 2030
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04175314: Severity of Periodontal Recession and Associated Risk Factors in France.
Official title: Severity of Periodontal Recession by Patient and Associated Risk Factors in France.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Periodontal Recessions
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2019-11-25
Enrollment: 240
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients are selected during a dental consultation.

Brief summary: The severity of periodontal recessions for each examined patient during dental consultation was evaluated. Moreover, the description of the number of periodontal recessions in patients with good health during dental consultation, the associated risk factors and evaluation of the number of recessions which need surgical therapy were realized.


Eligibility criteria: Inclusion Criteria:

Case:

* patients aged from 20 to 50 years
* patients with recession of more than 1mm
* patient with good health
* patients who aggreed to participate to the study

Controls:

* patients aged from 20 to 50 years
* patients with no recession or recession less than 1mm
* patient with good health
* patients who aggreed to participate to the study

Exclusion Criteria:

* patients with periodontitis
* patients with recession of Class III and IV of modified Miller classification
* patients with previous muco-gingival surgery
* patients pregnant, breatheeding
* patients refusing to participate to the study

Primary outcomes:
measure: Evaluation of periodontal recession severity
timeFrame: Observation at day 1
Secondary outcomes:
measure: Number of recessions for each patient
timeFrame: Observation at day 1
measure: Associated risk factors
timeFrame: Observation at day 1
measure: Number of participants with recession-related adverse events as assessed by questionnaire
timeFrame: Observation at day 1
measure: Frequency of periodontal recession according to the modified Miller classifcation
timeFrame: Observation at day 1
Other outcomes:
Locations:
city: Créteil
country: France
facility: CHU Henri Mondor
city: Montpellier
country: France
facility: CHU
city: Nancy
country: France
facility: CHU
city: Nice
country: France
facility: CHU Saint Roch
city: Toulouse
country: France
facility: CHU Ragueil
Study officials:
affiliation: Central Hospital
name: Catherine BISSON
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01623414: Sunlight Exposure and Vitamin D Status of Children of South Asian Ethnicity Living in the UK
Official title: Sunlight Exposure and Vitamin D Status of Children of South Asian Ethnicity Living in the UK
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Volunteers
Lead sponsor: University of Manchester
Sponsor class: OTHER
First posted: 2012-06-20
Enrollment: 131
Sex: ALL
Minimum age (years): 12
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Schoolchildren of South Asian ethnicity in Greater Manchester

Brief summary: The purpose of this study is to examine the amount of sunlight exposure and vitamin D status of adolescent schoolchildren of South Asian ethnicity in each season throughout the year.


Eligibility criteria: Inclusion Criteria:

* Healthy schoolchildren aged 12-15 years
* Sun-reactive skin type V (naturally brown skin)
* South Asian ethnicity
* Male or female

Exclusion Criteria:

* History of photosensitivity disorder
* Non-ambulant

Primary outcomes:
measure: Change in serum concentration of 25-hydroxyvitamin D
timeFrame: 1 year
Secondary outcomes:
measure: Change in sunlight exposure received
timeFrame: 1 year
measure: Change in dietary intake of vitamin D
timeFrame: 1 year
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: Salford Royal NHS Foundation Trust
Study officials:
affiliation: University of Manchester
name: Lesley Rhodes, MD FRCP(UK)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01107314: Vasopressin Deficiency in Hemorrhagic Shock
Official title: Vasopressin Deficiency in Hemorrhagic Shock
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Body Response to Trauma
Lead sponsor: The University of Texas Health Science Center at San Antonio
Sponsor class: OTHER
First posted: 2010-04-20
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Maximum age (years): 98
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: observational study - trauma patients admitted to University Hospital

Brief summary: In this study we hope to delineate the typical vasoactive mediator response of trauma patients to shock. We plan to assess serum levels of vasopressin and also catecholamines, angiotensin, and cortisol during resuscitation of trauma patients to delineate high risk populations for vasopressin deficiency.

Detailed description: This is a prospective observational study. The only research-driven procedure will be the removal of blood samples at designated time points(total blood removed 48 cc per patient). Hemodynamic, fluid infusion and agitation/pain data (RAMSEY Score) will prospectively be collected for research purposes. We will collect data from a convenience sample of patients (when research staff is available) over a one year period.

Eligibility criteria: Inclusion Criteria:

* Patient is a male or female patient presumed to be at least 18 years of age;
* Patient has a reported or actual systolic blood pressure \< 90 mmHg within 1 hour of arrival to the Emergency Room;
* Patient has clinical evidence of acute traumatic injury;

Exclusion Criteria:

* Patient is asystolic or requires CPR prior to arrival;
* Patient was transferred from an outside facility
* Patient known to be pregnant
* Patient known to be prisoner

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: UTHSCSA
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center at San Antonio
name: Stephen M Cohn, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04132414: Cerebral NIRS Monitoring During Anesthesia in Neonates and Infants
Official title: Monitoring Of REgional Cerebral Oxygenation (rcSO2 ) With Near INFrared SpectrOscopy (NIRS) During Non-cardiac Surgery in Preterms, Neonates and Infants in Addition to Standard Monitoring to Guide Intraoperative Management
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cerebral Oxygenation
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
First posted: 2019-10-18
Enrollment: 40
Sex: ALL
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The brain is a very vulnerable organ, especially in premature babies, newborns and infants. However, during anesthesia, the oxygenation of the brain can only be monitored indirectly and insufficiently. Near-infrared spectroscopy (NIRS) is an established monitoring method in other areas (e.g., neonatology, cardiac anesthesia), which provides non-invasive information about the regional oxygen supply of the brain. The integration of this monitoring device into the anaesthesiological care for neonates and infants could reduce the risk of cerebral hypoxia. The planned study investigates whether the use of NIRS in anesthetized children up to 6 months can prevent or influence the occurrence of cerebral hypoxia.


Eligibility criteria: Inclusion Criteria:

* Expected duration of Anesthesia \>45 minutes
* Intervention/surgery in the operating room

Exclusion Criteria:

* Impossibility to place cerebral NIRS sensor
* Known cerebral pathology
* Missing parental consent
* Congenial cardiac condition with right to left shunt
* Cardiac surgery

Primary outcomes:
measure: Cerebral hypoxic burden
timeFrame: 1 day
Secondary outcomes:
measure: Fluid administration
timeFrame: 1 day
measure: Number of participants with Vasopressor or Inotrope administered
timeFrame: 1 day
measure: Number of participants with erythrocyte administration
timeFrame: 1 day
measure: Fraction of inspired oxygen
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
affiliation: Medical University of Graz
name: Stefan Heschl, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: